 Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: Analysis of the efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma

Br J Cancer: Analysis of the efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma

 Last Update: 2021-11-12
 Source: Internet
 Author: User

Tags

p53 mutation cancer

fight cancer naturally

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Malignant pleural mesothelioma (MPM) is an aggressive, locally aggressive, and incurable pleural malignant tumor.
Its incidence is related to exposure to asbestos at work
.

Although many countries have banned the use of asbestos, asbestos insulated buildings are still spread all over the world, and some countries are still manufacturing and using large amounts of asbestos

Malignant pleural mesothelioma (MPM) is an aggressive, locally aggressive, and incurable pleural malignant tumor.

Previous studies have shown that genetic mutations in BAP1 and other cancer susceptibility genes (such as PALB2, BRCA2, CHEK2, MLH1, etc.
) have been found in about 10-15% of MPM patients
.

There are currently limited treatment options for patients with advanced MPM
.

Cisplatin combined with pemetrexed has become the standard treatment strategy for patients with advanced MPM

Adding bevacizumab to chemotherapy can moderately improve overall survival, but not all countries adopt this treatment strategy

The effect of CDK4/6 inhibitor on MPM cell cycle and senescence

This study aims to reveal the anti-tumor efficacy of CDK4/6 inhibitors in preclinical models of MPM and to study their potential in the treatment of MPM
.

The researchers also assessed the prognostic impact of CDK4 or CDK6 overexpression in primary tumors of MPM patients by analyzing publicly available MPM transcriptome data

This study aims to reveal the anti-tumor efficacy of CDK4/6 inhibitors in preclinical models of MPM and to study their potential in the treatment of MPM

The overall survival rate of two groups of MPM patients with different expression levels of CDK4 and CDK6

All in all, the results of the study revealed that CDK4/6 inhibitors mainly reduce the proliferation of MPM cells by promoting cell cycle arrest in the G1 phase and promoting cell senescence
.

This preclinical study also provides certain theoretical evidence for clinical evaluation of the efficacy of CDK4/6 inhibitors on MPM

CDK4/6 inhibitors mainly reduce the proliferation of MPM cells by promoting the arrest of the cell cycle in the G1 phase and promoting cell senescence

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.